540 related articles for article (PubMed ID: 26569098)
1. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
[TBL] [Abstract][Full Text] [Related]
2. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
Paulsen JS; Long JD; Ross CA; Harrington DL; Erwin CJ; Williams JK; Westervelt HJ; Johnson HJ; Aylward EH; Zhang Y; Bockholt HJ; Barker RA;
Lancet Neurol; 2014 Dec; 13(12):1193-201. PubMed ID: 25453459
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.
Killoran A; Biglan KM; Jankovic J; Eberly S; Kayson E; Oakes D; Young AB; Shoulson I
Neurology; 2013 May; 80(22):2022-7. PubMed ID: 23624566
[TBL] [Abstract][Full Text] [Related]
4. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
[TBL] [Abstract][Full Text] [Related]
5. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
[TBL] [Abstract][Full Text] [Related]
6. Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).
Quaid KA; Eberly SW; Kayson-Rubin E; Oakes D; Shoulson I;
Clin Genet; 2017 Jun; 91(6):824-831. PubMed ID: 27740685
[TBL] [Abstract][Full Text] [Related]
7. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.
Marder K; Gu Y; Eberly S; Tanner CM; Scarmeas N; Oakes D; Shoulson I;
JAMA Neurol; 2013 Nov; 70(11):1382-8. PubMed ID: 24000094
[TBL] [Abstract][Full Text] [Related]
8. Phenotype-genotype discrepancies in the prospective Huntington at-risk observational study.
Shoulson I; Eberly S; Oakes D; Kayson E; Young AB;
Ann Clin Transl Neurol; 2019 Jun; 6(6):1046-1052. PubMed ID: 31211168
[TBL] [Abstract][Full Text] [Related]
9. Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic Approach.
Mariani LL; Tesson C; Charles P; Cazeneuve C; Hahn V; Youssov K; Freeman L; Grabli D; Roze E; Noël S; Peuvion JN; Bachoud-Levi AC; Brice A; Stevanin G; Durr A
JAMA Neurol; 2016 Sep; 73(9):1105-14. PubMed ID: 27400454
[TBL] [Abstract][Full Text] [Related]
10. Severity of cognitive impairment in juvenile and late-onset Huntington disease.
Gómez-Tortosa E; del Barrio A; García Ruiz PJ; Pernaute RS; Benítez J; Barroso A; Jiménez FJ; García Yébenes J
Arch Neurol; 1998 Jun; 55(6):835-43. PubMed ID: 9626775
[TBL] [Abstract][Full Text] [Related]
11. Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes.
Garcia TP; Wang Y; Shoulson I; Paulsen JS; Marder K
J Huntingtons Dis; 2018; 7(4):337-344. PubMed ID: 30400103
[TBL] [Abstract][Full Text] [Related]
12. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants.
Marder K; Zhao H; Eberly S; Tanner CM; Oakes D; Shoulson I;
Neurology; 2009 Aug; 73(5):385-92. PubMed ID: 19652143
[TBL] [Abstract][Full Text] [Related]
13. Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.
Long JD; Mills JA; Leavitt BR; Durr A; Roos RA; Stout JC; Reilmann R; Landwehrmeyer B; Gregory S; Scahill RI; Langbehn DR; Tabrizi SJ;
JAMA Neurol; 2017 Nov; 74(11):1352-1360. PubMed ID: 28975278
[TBL] [Abstract][Full Text] [Related]
14. Preparing for preventive clinical trials: the Predict-HD study.
Paulsen JS; Hayden M; Stout JC; Langbehn DR; Aylward E; Ross CA; Guttman M; Nance M; Kieburtz K; Oakes D; Shoulson I; Kayson E; Johnson S; Penziner E;
Arch Neurol; 2006 Jun; 63(6):883-90. PubMed ID: 16769871
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.
Huntington Study Group TREND-HD Investigators
Arch Neurol; 2008 Dec; 65(12):1582-9. PubMed ID: 19064745
[TBL] [Abstract][Full Text] [Related]
16. A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.
Ciosi M; Maxwell A; Cumming SA; Hensman Moss DJ; Alshammari AM; Flower MD; Durr A; Leavitt BR; Roos RAC; ; ; Holmans P; Jones L; Langbehn DR; Kwak S; Tabrizi SJ; Monckton DG
EBioMedicine; 2019 Oct; 48():568-580. PubMed ID: 31607598
[TBL] [Abstract][Full Text] [Related]
17. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
[TBL] [Abstract][Full Text] [Related]
18. Association of CAG Repeat Length in the Huntington Gene With Cognitive Performance in Young Adults.
Schultz JL; Saft C; Nopoulos PC
Neurology; 2021 May; 96(19):e2407-e2413. PubMed ID: 33692166
[TBL] [Abstract][Full Text] [Related]
19. Exploring the correlates of intermediate CAG repeats in Huntington disease.
Ha AD; Jankovic J
Postgrad Med; 2011 Sep; 123(5):116-21. PubMed ID: 21904093
[TBL] [Abstract][Full Text] [Related]
20. Clinical manifestations of homozygote allele carriers in Huntington disease.
Cubo E; Martinez-Horta SI; Santalo FS; Descalls AM; Calvo S; Gil-Polo C; Muñoz I; Llano K; Mariscal N; Diaz D; Gutierrez A; Aguado L; Ramos-Arroyo MA;
Neurology; 2019 Apr; 92(18):e2101-e2108. PubMed ID: 30867264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
